Passage Bio, Inc. (PASG) - Multiplikator Forward P/S
Insurance fund reimbursement for rare brain pathology therapies creates the financial foundation for Passage Bio, Inc. (PASG). The projected P/S multiple reflects market expectations, where the mark characterizes this parameter. Passage Bio, Inc. (PASG) relies on AAV-vector gene delivery to treat orphan diseases, yet intense investor pressure is forcing the company to accelerate trials in competition with global players.
Rincian metrik komprehensif lan analitis passagebio.com (PASG)
- rega saham lan target rega konsensus:
- indikator kapitalisasi pasar:
- statistik nilai buku emiten:
- rincian struktur utang lan likuiditas bisnis:
Rasio Total Utang marang Ekuitas Passage Bio, Inc.|PASG - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal Passage Bio|PASG - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku Passage Bio, Inc.|PASG - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Passage Bio|Indikator likuiditas cepet passagebio.com
- rincian asil keuangan lan kelipatan valuasi:
PASG - Asil keuangan resik|Bathi sing dikarepake Passage Bio, Inc.|PASG - Kapitalisasi marang bathi resik|Pangali Forward P/E Passage Bio|PASG - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Passage Bio, Inc.|PASG - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) Passage Bio|PASG - Bathi resik saben saham sajroning taun lumaku|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan passagebio.com|PASG - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Passage Bio, Inc.
- indikator volume dodolan lan pendapatan:
Analisis komprehensif perusahaan:PASG (Passage Bio Corp)
To protect capital from volatility, it is crucial for investors to understand the extent to which the market capitalization of Passage Bio, Inc. (PASG) is justified by future sales expectations. The global expansion of CNS gene therapy via AAV vectors drives the projected P/S trend, which measures the market's willingness to pay a premium for future revenue; a sharp rise in the line signals optimism regarding the commercial capture of the neuropharma sector, but warns of the risk of overvalued assets.
Analisis pesaing Passage Bio, Inc.
Biogen - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan NBIX|Regencell - Multiplikator Forward P/S|AXSM: Rasio rega marang prakiraan pendapatan|ACAD: Multiplikator Forward P/S|XENE - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Viking Therapeutics, Inc.|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Supernus Pharmaceuticals, Inc. SUPN|Multiplikator forward rega marang pendapatan CPRX (Catalyst Pharmaceuticals Inc)|DNLI (Denali Corp) - Rega forward marang dodolan|Multiplikator Forward P/S HRMY (Harmony Biosciences)|Rasio kapitalisasi marang dodolan sing dikarepake biohavenpharma.com (BHVN)|AMLX - Rasio rega marang prakiraan pendapatan|TRVI (Trevi Therapeutics Inc) - Kapitalisasi marang prakiraan pendapatan|PRAX: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Anavex Life Sciences Corp|Multiplikator forward rega marang pendapatan CBLL|Prothena Corporation (PRTA) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Alector, Inc. (ALEC)|ANNX: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S OMER (Omeros)|Multiplikator Forward P/S Neurogene Therapeutics NGNE|ACIU - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake voyagertherapeutics.com VYGR|NMRA: Multiplikator Forward P/S|Prakiraan rega marang pendapatan Scilex Holding SCLX|Rasio rega marang prakiraan pendapatan Tevogen Bio Holdings, Inc.|Kapitalisasi marang prakiraan pendapatan ACOG (Alpha Cognition Corp)|Multiplikator Forward P/S CGTX|IKT - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Cassava Sciences - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Assertio Holdings ASRT|COYA - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan VTGN (Vistagen Therapeutics)|ovidrx.com (OVID) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep acumenpharm.com (ABOS)|Rasio rega marang prakiraan pendapatan CervoMed|Alterity Therapeutics Ltd - Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S CLNN|Multiplikator Forward P/S pepgen.com (PEPG)|Rasio rega marang prakiraan pendapatan Jupiter Neurosciences Inc JUNS|Rasio kapitalisasi marang dodolan sing dikarepake relmada.com (RLMD)|ANVS - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Grace Therapeutics, Inc. GRCE|AIFF: Multiplikator Forward P/S|Klotho Neurosciences (KLTO) - Multiplikator Forward P/S|NRSN (NeuroSense Therapeutics Ltd) - Multiplikator Forward P/S|RVPH - Prakiraan rega marang pendapatan|Multiplikator Forward P/S MTVA|NRXS - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Helius Medical Technologies - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan NEUP|Minerva Neurosciences - Multiplikator Forward P/S|ATHA: Rasio rega marang prakiraan pendapatan|ADXN: Multiplikator Forward P/S|ALZN - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Cyclerion Therapeutics Inc.|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Protagenic PTIX|Multiplikator forward rega marang pendapatan KTTA (Pasithea Therapeutics)|CRGT (cortigent.com) - Rega forward marang dodolan|Multiplikator Forward P/S ATXI (Avenue Therapeutics, Inc.)|Rasio kapitalisasi marang dodolan sing dikarepake Brainstorm Cell Therapeutics Inc. (BCLI)|CARA - Rasio rega marang prakiraan pendapatan|CHRO (Chromocell) - Kapitalisasi marang prakiraan pendapatan|ELYM: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Intra-Cellular Therapies, Inc.|Multiplikator forward rega marang pendapatan LBPH|Marinus Pharmaceuticals Inc (MRNS) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan NKGen (NKGN)|NRBO: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S SAGE (Sage Therapeutics, Inc.)|Multiplikator Forward P/S synaptogen.com SNPX|TRVN - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Vigil Neuroscience VIGL|WENA: Multiplikator Forward P/S|Prakiraan rega marang pendapatan Cerevel Corp CERE
